mesna and Kidney-Failure--Chronic

mesna has been researched along with Kidney-Failure--Chronic* in 3 studies

Trials

2 trial(s) available for mesna and Kidney-Failure--Chronic

ArticleYear
Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients.
    Blood purification, 2009, Volume: 27, Issue:3

    Increased plasma total homocysteine (tHcy) is a risk factor for the development of atherosclerosis and thrombosis present in over 90% of patients with end-stage renal disease (ESRD). We hypothesized that 12 mg/kg intravenous mesna administered predialysis would cause a significant decrease in plasma tHcy compared to placebo.. Patients with ESRD were recruited for 1- and 4-week placebo-controlled, cross-over studies. Intravenous 12 mg/kg mesna or placebo was administered 3 times weekly predialysis.. One week of 12 mg/kg intravenous mesna significantly decreased predialysis plasma tHcy by 12.8 +/- 7.8% (placebo 23.4 +/- 8.0 micromol/l vs. mesna 20.5 +/- 7.6 micromol/l, p = 0.0044). Four weeks of treatment yielded no significant decline in predialysis plasma tHcy (placebo 18.3 +/- 8.5 micromol/l vs. mesna 18.7 +/- 6.3 micromol/l, p = 0.41).. Although 12 mg/kg mesna significantly enhances tHcy excretion, prolonged treatment causes no change in plasma tHcy.

    Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Homocysteine; Humans; Hyperhomocysteinemia; Kidney Failure, Chronic; Male; Mesna; Middle Aged; Pilot Projects; Renal Dialysis

2009
Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:4

    Increased plasma total homocysteine is a graded, independent risk factor for the development of atherosclerosis and thrombosis. More than 90% of patients with end-stage renal disease have hyperhomocysteinemia despite vitamin supplementation. It was shown in previous studies that a single intravenous dose of mesna 5 mg/kg caused a drop in plasma total homocysteine that was significantly lower than predialysis levels 2 d after dosing. It was hypothesized 5 mg/kg intravenous mesna administered thrice weekly, before dialysis, for 8 wk would cause a significant decrease in plasma total homocysteine compared with placebo.. Patients with end-stage renal disease were randomly assigned to receive either intravenous mesna 5 mg/kg or placebo thrice weekly before dialysis. Predialysis plasma total homocysteine concentrations at weeks 4 and 8 were compared between groups by paired t test.. Mean total homocysteine at 8 wk in the placebo group was 24.9 micromol/L compared with 24.3 micromol/L in the mesna group (n = 22 [11 pairs]; mean difference 0.63). Interim analysis at 4 wk also showed no significant difference between mesna and placebo (n = 32 [16 pairs]; placebo 26.3 micromol/L, mesna 24.5 micromol/L; mean difference 1.88). Multivariable adjustments for baseline characteristics did not alter the analysis. Plasma mesna seemed to reach steady-state concentrations by 4 wk.. It is concluded that 5 mg/kg mesna does not lower plasma total homocysteine in hemodialysis patients and that larger dosages may be required.

    Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Homocysteine; Humans; Hyperhomocysteinemia; Injections, Intravenous; Kidney Failure, Chronic; Male; Mesna; Renal Dialysis; Treatment Outcome

2008

Other Studies

1 other study(ies) available for mesna and Kidney-Failure--Chronic

ArticleYear
The effect of mesna on plasma total homocysteine concentration in hemodialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2007, Volume: 49, Issue:1

    Plasma total homocysteine (tHcy) level is an independent risk factor for the development of atherosclerosis. The degree of risk in most of the population is decreased by using dietary vitamin supplementation; however, more than 90% of patients with end-stage renal disease have increased tHcy levels despite supplementation. Only a small fraction of tHcy is removed by hemodialysis because of extensive disulfide bonding to albumin. The objective of this study is to determine whether a single intravenous dose of mesna, a thiol-containing drug analogue of taurine, facilitates tHcy clearance during hemodialysis.. Initial in vitro thiol exchange tests were performed with mesna in plasma from dialysis patients. Mesna, 300 micromol/L (49.2 mg/L), was incubated with plasma at 37 degrees C, and free homocysteine was measured at various times. In vivo, mesna activity was tested in 10 hemodialysis patients by administering 2.5 or 5.0 mg/kg of mesna intravenously at the beginning of a treatment cycle. Blood samples were drawn throughout dialysis, and plasma tHcy levels were compared with those obtained from a previous dialysis session in which mesna was not administered.. In vitro, mesna liberated 36.5% +/- 2.5% of protein-bound homocysteine in 30 minutes. In vivo, a single 2.5-mg/kg dose of mesna was ineffective; however, at 5.0 mg/kg, it caused a 55.2% +/- 3.9% decrease in plasma tHcy levels postdialysis compared with a 34.2% +/- 5.3% decrease with dialysis alone (P < 0.001).. Intravenous mesna causes a rapid decrease in plasma tHcy levels during hemodialysis.

    Topics: Adult; Aged; Aged, 80 and over; Female; Homocysteine; Humans; Kidney Failure, Chronic; Male; Mesna; Middle Aged; Pilot Projects; Renal Dialysis

2007